• Major indices opened sharply higher, with the Nasdaq leading gains at 1.7%.
  • A landmark Pfizer-White House drug pricing agreement sparked a 2.7% surge in health care stocks.
  • Investor sentiment strengthened despite weak jobs data and ongoing government shutdown concerns.

U.S. stock indices powered higher at the open on October 13, 2025, shaking off recent volatility as optimism about potential Federal Reserve interest-rate cuts and a blockbuster health care sector deal fueled a broad-based rally. The Dow Jones Industrial Average rose 0.48%, the S&P 500 gained 1.16%, and the technology-heavy Nasdaq Composite climbed 1.7%.

The strong opening followed a turbulent week dominated by fears over a partial U.S. government shutdown and persistent U.S.-China trade tensions. The rally was largely attributed to shifting expectations for monetary policy, with soft private-sector hiring data and persistent inflation leading investors to bet the Fed may move to cut rates sooner than previously anticipated.

A key catalyst for the session was the historic agreement between Pfizer and the White House to cut drug prices in return for tariff relief, according to people familiar with the matter. The deal ignited a powerful rally across the health care sector, which jumped 2.7% as a group. Major names including Biogen, Thermo Fisher, and Eli Lilly all posted double-digit percentage gains in early trading.

"The market is looking through the immediate noise of the shutdown and focusing on the potential for an accommodative pivot from the Fed," said a portfolio manager at a large institutional firm, who asked not to be named discussing client positions. "The health care news is providing a fundamental story to hang that optimism on."

Despite the positive momentum, the path forward remains uneven. The ongoing government shutdown has delayed the release of key economic reports, complicating the Fed's policy decisions and creating uncertainty for investors. Efforts to reach a bipartisan budget deal have stalled, according to congressional aides, leaving markets to grapple with the lack of official economic data.

A spokesperson for the White House did not immediately respond to a request for comment on the Pfizer agreement. Representatives for Pfizer declined to comment.

Sector rotation was notable, with health care and technology significantly outperforming while industrials and materials lagged behind. The S&P 500 and Nasdaq both notched new record highs during the session, with analysts from several major firms projecting further upside into 2025 and 2026, contingent on supportive Fed policy and steady GDP growth.

Correction: An earlier version of this article misstated the timing of the government shutdown. The shutdown is ongoing.